|  |
| --- |
| **Table S3. Infliximab: Efficacy of Off-Label Regimens** |
| **Dose Escalation** |
| Author, Year (Location) Study Design | N | Age mean (SD) | Gender n(%) male | Dose Escalation | Duration of Follow-up | Primary Outcome | Secondary Outcome |
| Chaudhari et al., 2001 (US), RCT [[10](#_ENREF_10)] | 33 | 10mg/kg: 35(11)5mg/kg: 51(14)Placebo: 45(12) | 10mg/kg: 8(73%)5mg/kg: 7(64%)Placebo: 8(73%) | Dose Escalation: IV 10mg/kg infliximab at weeks 0, 2, and 6 (n=11)Standard Dose: IV 5mg/kg infliximab at weeks 0, 2, and 6 (n=11) | 10 weeks | **PGA “good,” “excellent,” or “clear” at week 10**10mg/kg: 10/11 (91%)5mg/kg: 9/11 (82%)Placebo: 2/11 (18%)(p=0.0019 for 10mg/kg vs. placebo and p=0.0089 for 5mg/kg vs. placebo)**PGA “excellent” or “clear” at week 10**10mg/kg: 7/11 (64%)5mg/kg: 9/11 (82%)Placebo: 2/11 (18%) | **PASI 75 at week 10**10mg/kg: 8/11 (73%)5mg/kg: 9/11 (82%)Placebo: 2/11 (18%)(p=0.03 for 10mg/kg vs. placebo and p=0.0089 for 5mg/kg vs. placebo) |
| **Withdrawal & Retreatment** |
| Author, Year (Location) Study Design | N | Age mean (SD) | Gender n(%) male | Withdrawal Period | Retreatment Period | Primary Outcome | Secondary Outcome |
| Gottlieb et al., 2003 (US), Open-label [[11](#_ENREF_11)] | 33 | 10mg/kg: 35(11)5mg/kg: 51(14)Placebo: 45(12) | 10mg/kg: 8(73%)5mg/kg: 7(64%)Placebo: 8(73%) | After IV 10mg/kg infliximab (n=11) or 5mg/kg infliximab (n=11) at weeks 0, 2, and 6, “responders” (PGA “good” “excellent” or “clear”) were withdrawn until disease relapse. | At time of relapse (loss of at least half improvement in PASI score achieved at week 10), pts (n=9) were treated with a single-dose infusion of their originally randomized dose of infliximab through week 26.10mg/kg: 3/9 received one infusion5mg/kg: 3/9 received one infusion, 3/9 received two infusions | **Maintenance of PASI 75, PASI 50 through week 26 (retreatment not specified)**10mg/kg: 67%, 73%5mg/kg: 33%, 40% | **Time to loss of response**5mg/kg: after week 1410mg/kg: after week 18**Time to first retreatment**Ranged from week 22 to week 34 |
| Gottlieb et al., 2004 (US), RCT [[12](#_ENREF_12)] | 249 | Overall: 44(NR†)3mg/kg: 45(NR)5mg/kg: 44(NR) | Overall: 174(70%) 3mg/kg: 70(NR) 5mg/kg: 73(NR) | Pts who received 3mg/kg (n=99) or 5mg/kg (n=99) IV infliximab at weeks 0, 2, and 6 were withdrawn from therapy from weeks 6 to 26 | At week 26, pts with PGA “moderate” or “severe” were eligible for a single IV dose of their originally randomized assigned treatment (n=114) | **PASI 75 at week 10**3mg/kg: 71/99 (71.9%)5mg/kg: 87/99 (87.9%)Placebo: 3/51 (5.9%)(p<0.0001 for each comparison vs. placebo) | **PGA “clear” or “minimal” at week 10**3mg/kg: 71/99 (71.7%)5mg/kg: 89/99 (89.9%)Placebo: 5/51 (9.8%)(p<0.0001 for each comparison vs. placebo)**PGA clear, minimal, or mild at week 30 after retreatment at week 26**3mg/kg: 38%5mg/kg: 64%Placebo: 18% |
| Menter et al., 2007 (Canada, Europe, US), EXPRESS II RCT [[13](#_ENREF_13)] | 835 | 3mg/kg: 43.4(12.6)5mg/kg: 44.5(13.0) | 3mg/kg: NR(65.8%) 5mg/kg: NR(65.0%) | Pts who received 3mg/kg (n=313) or 5mg/kg (n=314) IV infliximab at weeks 0, 2, and 6 were withdrawn from therapy from weeks 6 to 14  | At week 14, pts were re-randomized to continuous infusions at 8-week intervals or intermittent (infusion when loss of PASI 75) regimens at their induction dose (n=595) | **PASI 75 at week 10 (week 4 of withdrawal period)**3mg/kg: 70.3%5mg/kg: 75.5%Placebo: 1.9%(p<0.001)**Intermittent infusion interval**Most common time interval for intermittent infusions was 4-8 weeks (data not shown) | **PGA “clear” or “excellent” at week 10 (week 4 of withdrawal period)**3mg/kg: 69.8%5mg/kg: 76.0%Placebo: 1%(p<0.001)**PGA “clear” or “excellent” at week 50**3mg/kg every-8-week: 46.9%3mg/kg interrupted: 31.7%5mg/kg every-8-week: 58.2%5mg/kg interrupted: 42.1%**PASI 90 at week 10 (week 4 of withdrawal period)**3mg/kg: 37.1%5mg/kg: 45.2%Placebo: 0.5%**PASI 75 at week 50**3mg/kg every-8-week: 43.8%3mg/kg interrupted: 25.4%5mg/kg every-8-week: 54.5%5mg/kg interrupted: 38.1% |

NR † = Not reported